- NYSE Euronext Profit Misses Expectations
- Oils Drag on Euro Shares, Barclays Beat Forecasts
- Nissan Forecasts Annual Loss, First Under CEO Ghosn
- LG Electronics to Cut $2.2 Billion Costs
- Germany's Economy Minister Glos Plans to Resign
- S.Korea January Producer Inflation at One-Year Low
- Britain's BG Offers $538 Million for Pure Energy
- Japan Machinery Orders Fall, Outlook Remains Bleak
- Vodafone, Hutchison to Merge Australia Businesses
- Yoshikami: Is It Time to Sell or Go Bargain Hunting?
- Is Pitney Bowes First Class?
- Lightning Round: UPS, Corning, Wyndham and More
- Lightning Round OT: Harley-Davidson, Hartford Financial and More
- Game Plan: Obama’s Second Honeymoon?
- Speculating on GMX Resources
- Cramer: 10 Reasons This Market’s Better Than You Think
- Subway Keeps Phelps
- Your First Move For Monday February 9th
- Ahead of the Bell-Principal Financial to report 4Q
- UPM to lay off 1,200 workers in Finland
- French-Romanian car maker resumes production
- UK to impose new visa requirements on South Africa
- Grenade found on Romanian train heading to Vienna
- Heidelberg Cement sees '08 pretax profit up 11 pct
- Up, down commodity prices leave farmers uneasy
- Chinalco shares up on talk of reshuffle, Rio deal
- Taiwanese exports plunged in January
Text Size 
NEW YORK - A Pfizer Inc. cancer drug has received a tenative recommendation from a review body of U.K. National Health Service, reversing previous guidance.
The recommendation means the service's review board has found the drug Sutent cost-effective for treating kidney cancer that is advanced or has spread through the body.
In draft guidance released Tuesday, the U.K.'s National Institute for Health and Clinical Excellence said it is still reviewing three other drugs but is not recommending them as a first-line treatment: Genentech and Roche's Avastin, Bayer's Nexavar and Wyeth's Torisel.
The institute had previously said in August that all four drugs could extend lives, but that the pricey drugs were not cost-effective.
The institute noted that Pfizer has agreed to provide the first cycle of Sutent to the health service for free.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes